* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Distinct effects of 11q aberrations on neuroblastoma with
Cancer epigenetics wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Metagenomics wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
History of genetic engineering wikipedia , lookup
Biology and consumer behaviour wikipedia , lookup
Polycomb Group Proteins and Cancer wikipedia , lookup
Minimal genome wikipedia , lookup
Gene therapy wikipedia , lookup
Epigenetics in learning and memory wikipedia , lookup
Ridge (biology) wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Oncogenomics wikipedia , lookup
Long non-coding RNA wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Pathogenomics wikipedia , lookup
Gene desert wikipedia , lookup
Public health genomics wikipedia , lookup
Gene nomenclature wikipedia , lookup
Saethre–Chotzen syndrome wikipedia , lookup
Genome evolution wikipedia , lookup
X-inactivation wikipedia , lookup
Epigenetics of human development wikipedia , lookup
Genome (book) wikipedia , lookup
Helitron (biology) wikipedia , lookup
Mir-92 microRNA precursor family wikipedia , lookup
Microevolution wikipedia , lookup
Genomic imprinting wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Gene expression programming wikipedia , lookup
Designer baby wikipedia , lookup
Gene expression profiling wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Supplementaries Supplementary table 1: Characteristics of patients and tumour samples of the four clinicogenetic subgroups normal_fav (A), normal_unfav (B), del11q_fav (C) and del11q_unfav (D). Indicated are the stage of disease according to INSS, the age at diagnosis (days), the genomic MYCN, 1p, 11q and 3p status according to FISH results (1, not amplified; n, not deleted; del, deletion; im, imbalance; n.d., not determined), the histological assessment according to Shimada (F, favourable; UF, unfavourable; n.d., not determined), the risk estimation according to the criteria of the German Neuroblastoma Trial NB2004 (LR, low risk; IR, intermediate risk; HR, high risk), the gene expression-based classification according to PAM by either cross validation (CV) or prediction (test set; LR, low risk; HR, high risk), the initial cytotoxic treatment, the current status of the patient (0, no event; 1, death of disease; 2, relapse or progression), the event-free and overall survival (EFS and OS; days), the treatment protocol according to which the patients were treated, and the neuroblastoma screening status (n, not screened; TP, true positive; FN, false negative). (*) indicates tumour samples used for promoter methylation analyses. Supplementary table 2: Genomic sequences amplified for methylation analysis of promoter regions. Indicated are the amplicon and gene name, the UCSC annotation template and the genomic sequence template, the oligonucleotide sequences used as primers, the strand direction, the target nucleotide sequence and sequence length, the number of CpG units within each amplified sequence, the chromosome, and the target start site and end on the chromosome. Supplementary table 3: Genes differentially expressed between clinico-genetic subgroups as determined by SAM: normal_fav vs. normal_unfav (A); del11q_fav vs. del11q_unfav (B); normal_fav vs. del11q_fav (C); normal_unfav vs. del11q_unfav (D); normal_fav vs. del11q_unfav (E); normal_unfav vs. del11q_fav (F). Indicated are the probe ID, the gene 1 symbol and gene description, the chromosomal location of the gene, the fold-change of expression between the subgroups under investigation, the SAM q-value, the false discovery rate (FDR), and the direction of regulation between the respective subgroups. “Up” and “down” refer to the average gene expression level in the second group of each comparison; e.g., 598 genes are significantly up-regulated in the normal_unfav subgroup in comparison to the normal_fav subgroup in supplementary table 3A. Supplementary table 4: Overlap of genes differentially expressed between distinct neuroblastoma subgroups: Overlap of transcripts with differential expression in normal_fav vs. normal_unfav and 11_fav vs. del11q_unfav neuroblastoma (A); overlap of transcripts with differential expression in normal_fav vs. del11q_unfav and 11_fav vs. del11q_unfav neuroblastoma (B); overlap of transcripts with differential expression in normal_fav vs. del11q_unfav and normal_unfav vs. del11q_unfav neuroblastoma (C). Indicated are the probe ID, the gene symbol and gene description, the chromosomal location of the gene, the fold-change of expression between the subgroups under investigation, and the direction of regulation between the respective subgroups as described in legend to supplementary table 3. Supplementary table 5: Whole genome aCGH analysis of neuroblastoma subgroups del11q_fav, del11q_unfav, normal_fav and normal_unfav. Aberrations of ≥2 Mb are indicated. CNA at 11q are given in bold; CNA at 11q of tumour NB062 is given in parenthesis since only a weak signal could be detected in this case. Supplementary table 6: Genes selected for promoter methylation analysis: Genes downregulated in del11q_unfav tumours in comparison to normal_unfav tumours (A); genes downregulated in del11q_unfav tumours in comparison to del11q_fav tumours (B). Indicated are the probe ID, the gene symbol and NCBI Reference Sequence ID, the fold-change and 2 direction of expression relating to del11q_unfav tumours, as well as the cytogenetic and genomic location of the gene. Supplementary figure 1: Overlap of genes differentially expressed between normal_fav vs. normal_unfav and del11q_fav vs. del11q_unfav (A), del11q_unfav vs. normal_fav and del11q_unfav vs. del11q_fav (B) as well as between del11q_unfav vs. normal_fav and del11q_unfav vs. normal_unfav (C). 3